CAD - Coronary Artery DiseaseNCT07451860
Chronic Total Occlusion and Triglyceride-Glucose Index
An observational study of CAD - Coronary Artery Disease and Chronic Total Occlusion (CTO), run by Kırıkkale University at 1 site in Turkey (Türkiye).
Trial summary
We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- CAD - Coronary Artery Disease, Chronic Total Occlusion (CTO), Triglycerid Glucose Index
- What is being tested?
- triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.
- How many people
- 200 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 15 Mar 2026to 15 Sep 2026
- How long will I take part?
- 1 Day
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study population will consist of adult patients (≥18 years of age) undergoing coronary angiography, who will be divided into two groups according to the presence or absence of chronic total occlusion (CTO).
Who may be able to join
- Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals
Who cannot join
- Patients <18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI >30 kg/m²), inaccessible patient records
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Turkey (Türkiye)1 site
Kırıkkale university
Kirikkale
RUKİYE GÖNEN ÖZDEMİR, +905054503953, rukiye_gonen@hotmail.com
About this study
Official title: The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease
We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.
- Being tested
- triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.Diagnostic test
As no previous studies have demonstrated the predictive value of the TyG index for chronic total occlusion (CTO), the present investigation provides a novel contribution to the literature. We hypothesize that the triglyceride-glucose (TyG) index will be significantly higher in patients with chronic total occlusion (CTO) compared to those without CTO.
| Study group | Role | What they receive |
|---|---|---|
| Non CTO | CTO (chronic total occlusion) Receives: Diagnostic Test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2. | |
| CTO | CTO (chronic total occlusion) Receives: Diagnostic Test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2. |
What is being measured
The primary outcome is the main question the study is designed to answer.
The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples.
Measured: 1 Year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start15 Mar 2026 (estimated)
- Primary completion15 Jul 2026 (estimated)
- Study completion15 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CAD - Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 200 participants (estimated)
- Target duration
- 1 Day
Sponsor and investigators
- Lead sponsor
- Kırıkkale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Rukiye Gonen Ozdemir, Kırıkkale University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07451860
- Sponsor's protocol ID
- 2026.02.17
- Status last verified
- Feb 2026
- First submitted
- 28 Feb 2026
- Last updated
- 5 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT07451860
- Acronym / sponsor ID
- 2026.02.17
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Kırıkkale UniversityUniversity, hospital or other
- Study start
- 15 Mar 2026 (estimated)
- Primary completion
- 15 Jul 2026 (estimated)
- Study completion
- 15 Sep 2026 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 1 Day
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Non CTO | – | Diagnostic Test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.CTO (chronic total occlusion) |
| CTO | – | Diagnostic Test: triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.CTO (chronic total occlusion) |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study population will consist of adult patients (≥18 years of age) undergoing coronary angiography, who will be divided into two groups according to the presence or absence of chronic total occlusion (CTO).
Key inclusion criteria (1 listed)
- Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals
Key exclusion criteria (1 listed)
- Patients <18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI >30 kg/m²), inaccessible patient records
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| triglyceride-glucose (TyG) index was calculated from routinely obtained blood samples using the formula: Triglyceride (mg/dL) × Glucose (mg/dL) / 2.As no previous studies have demonstrated the predictive value of the TyG index for chronic total occlusion (CTO), the present investigation provides a novel contribution to the literature. We hypothesize that the triglyceride-glucose (TyG) index will be significantly higher in patients with chronic total occlusion (CTO) compared to those without CTO. | Diagnostic test | CTO, Non CTO |
Primary outcome
The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples.
Time frame: 1 Year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Mar 2026.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for CAD - Coronary Artery Disease
Not yet recruitingPhase 1/2
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Heterozygous Familial Hypercholesterolemia (HeFH)
Active, not recruitingPhase 3
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
Coronary Artery Disease
Active, not recruiting
Troponin in Acute Chest Pain to Risk Stratify and Guide EffecTive Use of Computed Tomography Coronary Angiography
Coronary Artery Disease
Recruiting
A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Understanding and Management of Coronary Calcium (The Optimal Trial)
Cardiovascular Diseases, Myocardial Ischemia
Active, not recruitingPhase 4
Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization
Coronary Artery Disease, Atherosclerosis of Coronary Artery
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of CAD - Coronary Artery Disease and Chronic Total Occlusion (CTO), run by Kırıkkale University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 5 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact RUKİYE GÖNEN ÖZDEMİR (+905054503953, rukiye_gonen@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The primary outcome measure will be the difference in the triglyceride-glucose (TyG) index between patients with chronic total occlusion (CTO) and those without CTO, assessed from routinely obtained blood samples. (time frame: 1 Year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Mar 2026.